Binet 分期与肿瘤体积对慢性淋巴细胞白血病治疗结果的影响

IF 0.8 Q3 MEDICINE, GENERAL & INTERNAL
Nigerian Postgraduate Medical Journal Pub Date : 2024-01-01 Epub Date: 2024-02-07 DOI:10.4103/npmj.npmj_246_23
Anazoeze Jude Madu, Helen Chioma Okoye, Ebele Adaobi Muoghalu, Angela Ogechukwu Ugwu, Augustine Nwakuche Duru, Charles Emeka Nonyelu, Ikechukwu Okwudili Anigbogu, Chinedu Anthony Ezekekwu
{"title":"Binet 分期与肿瘤体积对慢性淋巴细胞白血病治疗结果的影响","authors":"Anazoeze Jude Madu, Helen Chioma Okoye, Ebele Adaobi Muoghalu, Angela Ogechukwu Ugwu, Augustine Nwakuche Duru, Charles Emeka Nonyelu, Ikechukwu Okwudili Anigbogu, Chinedu Anthony Ezekekwu","doi":"10.4103/npmj.npmj_246_23","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Most of the predictive tools put up to prognosticate treatment outcomes in patients with chronic lymphocytic leukaemia (CLL) are not easily available and affordable in our resource-constrained environment.</p><p><strong>Aim: </strong>The aim of this study was to evaluate the impact of staging and some tumour bulk on treatment outcomes of persons with CLL, Enugu, Nigeria.</p><p><strong>Patients and methods: </strong>This is a 10-year review of the CLL data from the haemato-oncology unit of a Nigerian tertiary hospital to evaluate the impact of staging and tumour bulk indicators. Data were retrieved from the case notes of 102 patients with CLL receiving care at the facility. Data of interest include basic demographic variables, clinical features including spleen size and disease staging and blood counts. Statistical analysis was done using SPSS version 22.</p><p><strong>Results: </strong>The median absolute lymphocyte count (ALC) was 108.05 (confidence interval [CI] = 50.8-201.3, interquartile range [IQR] = 124.4) ×109/L, and duration of survival for the study cohort was 5.5 (CI = 3.5-31.9, IQR = 27) months. Majority (69, 79.3%) were in Stage C. The Binet stage showed a significant association with the ALC (r = 0.338; P = 0.002) but not with spleen size (r = 0.198; P = 0.056). The duration of survival only showed a significant inverse relationship with the ALC (r = 0.35, P = 0.006) but with neither the Binet stage (r = 0.103, P = 0.431) nor spleen size (r = 0.184, P = 0.116).</p><p><strong>Conclusion: </strong>In CLL patients, ALC at presentation correlates with the duration of survival. We recommend that the ALC at presentation be used as a prognostic marker in our clime.</p>","PeriodicalId":19720,"journal":{"name":"Nigerian Postgraduate Medical Journal","volume":null,"pages":null},"PeriodicalIF":0.8000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impact of Binet Staging versus Tumour Bulk on Treatment Outcome in Chronic Lymphocytic Leukaemia.\",\"authors\":\"Anazoeze Jude Madu, Helen Chioma Okoye, Ebele Adaobi Muoghalu, Angela Ogechukwu Ugwu, Augustine Nwakuche Duru, Charles Emeka Nonyelu, Ikechukwu Okwudili Anigbogu, Chinedu Anthony Ezekekwu\",\"doi\":\"10.4103/npmj.npmj_246_23\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Most of the predictive tools put up to prognosticate treatment outcomes in patients with chronic lymphocytic leukaemia (CLL) are not easily available and affordable in our resource-constrained environment.</p><p><strong>Aim: </strong>The aim of this study was to evaluate the impact of staging and some tumour bulk on treatment outcomes of persons with CLL, Enugu, Nigeria.</p><p><strong>Patients and methods: </strong>This is a 10-year review of the CLL data from the haemato-oncology unit of a Nigerian tertiary hospital to evaluate the impact of staging and tumour bulk indicators. Data were retrieved from the case notes of 102 patients with CLL receiving care at the facility. Data of interest include basic demographic variables, clinical features including spleen size and disease staging and blood counts. Statistical analysis was done using SPSS version 22.</p><p><strong>Results: </strong>The median absolute lymphocyte count (ALC) was 108.05 (confidence interval [CI] = 50.8-201.3, interquartile range [IQR] = 124.4) ×109/L, and duration of survival for the study cohort was 5.5 (CI = 3.5-31.9, IQR = 27) months. Majority (69, 79.3%) were in Stage C. The Binet stage showed a significant association with the ALC (r = 0.338; P = 0.002) but not with spleen size (r = 0.198; P = 0.056). The duration of survival only showed a significant inverse relationship with the ALC (r = 0.35, P = 0.006) but with neither the Binet stage (r = 0.103, P = 0.431) nor spleen size (r = 0.184, P = 0.116).</p><p><strong>Conclusion: </strong>In CLL patients, ALC at presentation correlates with the duration of survival. We recommend that the ALC at presentation be used as a prognostic marker in our clime.</p>\",\"PeriodicalId\":19720,\"journal\":{\"name\":\"Nigerian Postgraduate Medical Journal\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nigerian Postgraduate Medical Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/npmj.npmj_246_23\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/2/7 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nigerian Postgraduate Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/npmj.npmj_246_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/7 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:目的:本研究旨在评估分期和肿瘤体积对尼日利亚埃努古CLL患者治疗效果的影响:本研究对尼日利亚一家三级医院血液肿瘤科的CLL数据进行了10年回顾,以评估分期和肿瘤体积指标的影响。数据取自在该医院接受治疗的 102 名 CLL 患者的病例记录。相关数据包括基本人口统计学变量、临床特征(包括脾脏大小、疾病分期和血细胞计数)。统计分析采用 SPSS 22 版本:中位绝对淋巴细胞计数(ALC)为 108.05(置信区间 [CI] = 50.8-201.3,四分位数间距 [IQR] = 124.4)×109/L,研究队列的生存期为 5.5(CI = 3.5-31.9,IQR = 27)个月。Binet分期与ALC(r = 0.338; P = 0.002)有显著相关性,但与脾脏大小(r = 0.198; P = 0.056)无显著相关性。生存期仅与ALC(r = 0.35,P = 0.006)呈显著的反比关系,但与Binet分期(r = 0.103,P = 0.431)和脾脏大小(r = 0.184,P = 0.116)均无关系:结论:在CLL患者中,发病时的ALC与生存期有关。结论:在 CLL 患者中,发病时的 ALC 与存活时间相关。我们建议将发病时的 ALC 作为我们当地的预后指标。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Impact of Binet Staging versus Tumour Bulk on Treatment Outcome in Chronic Lymphocytic Leukaemia.

Background: Most of the predictive tools put up to prognosticate treatment outcomes in patients with chronic lymphocytic leukaemia (CLL) are not easily available and affordable in our resource-constrained environment.

Aim: The aim of this study was to evaluate the impact of staging and some tumour bulk on treatment outcomes of persons with CLL, Enugu, Nigeria.

Patients and methods: This is a 10-year review of the CLL data from the haemato-oncology unit of a Nigerian tertiary hospital to evaluate the impact of staging and tumour bulk indicators. Data were retrieved from the case notes of 102 patients with CLL receiving care at the facility. Data of interest include basic demographic variables, clinical features including spleen size and disease staging and blood counts. Statistical analysis was done using SPSS version 22.

Results: The median absolute lymphocyte count (ALC) was 108.05 (confidence interval [CI] = 50.8-201.3, interquartile range [IQR] = 124.4) ×109/L, and duration of survival for the study cohort was 5.5 (CI = 3.5-31.9, IQR = 27) months. Majority (69, 79.3%) were in Stage C. The Binet stage showed a significant association with the ALC (r = 0.338; P = 0.002) but not with spleen size (r = 0.198; P = 0.056). The duration of survival only showed a significant inverse relationship with the ALC (r = 0.35, P = 0.006) but with neither the Binet stage (r = 0.103, P = 0.431) nor spleen size (r = 0.184, P = 0.116).

Conclusion: In CLL patients, ALC at presentation correlates with the duration of survival. We recommend that the ALC at presentation be used as a prognostic marker in our clime.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Nigerian Postgraduate Medical Journal
Nigerian Postgraduate Medical Journal MEDICINE, GENERAL & INTERNAL-
CiteScore
1.90
自引率
0.00%
发文量
52
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信